Trial NCT03517722

View at ClinicalTrials.gov 
Org. Study IDs: CR108440
Secondary IDs: 2017-001489-53 CNTO1275SLE3001

Last trial update was posted on 2024-01-03

MeSH Interventions

Ustekinumab

MeSH Conditions

Lupus Erythematosus, Systemic

Other Conditions


Stopping Reasons

Study terminated early as a result of the outcome of the pre-planned Interim Analysis

Limitations And Caveats

Due to study termination, the open-label extension phase didn't reach the planned duration till Week 176. However, participants were assessed for safety up to Week 130 (that is, after study termination) and received study drug up to Week 113.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID